uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution
Careggi Univ Hosp, Dept Biomed, Immunoallergol Unit, Florence, Italy.
Univ Florence, Ctr Res Transfer & High Educ DENOTHE, Florence, Italy;Univ Florence, Dept Expt & Clin Med, Florence, Italy.
Careggi Univ Hosp, Dept Biomed, Immunoallergol Unit, Florence, Italy.
Univ Florence, Ctr Res Transfer & High Educ DENOTHE, Florence, Italy;Univ Florence, Dept Expt & Clin Med, Florence, Italy.
Show others and affiliations
2018 (English)In: Allergy. European Journal of Allergy and Clinical Immunology, ISSN 0105-4538, E-ISSN 1398-9995, Vol. 73, no 11, p. 2172-2181Article in journal (Refereed) Published
Abstract [en]

Background: Infliximab (IFX) carries potential risk of immunogenicity with the production of anti-drug antibodies (ADA). ADA may belong to different isotypes and are usually measured by ELISA bridging assay. This test is not designed to detect IgG4 antibodies. The aim was to measure IgG4 anti-IFX antibodies in a cohort of IFX-treated patients and to evaluate their relationship with ADA and their clinical impact.

Methods: Anti-drug antibodies were detected using a bridging ELISA in the serum of 222 treated patients with different clinical outcomes to IFX. The same samples were analyzed for IgG4 anti-IFX antibodies using an experimental ImmunoCAP assay with reduced serum IgG4 background levels. A longitudinal evaluation was performed in a subgroup of 38 patients to define the temporal evolution of IgG4 anti-IFX.

Results: IgG4 anti-IFX was found in 26.6% of patients. Eighty of 222 patients were ADA+ (36%) and the majority (57/80, 71.3%) had IgG4 anti-IFX. Two IgG4-positive but ADA-negative patients were identified. IgG4 anti-IFX levels correlated with the serum levels of ADA. IgG4 anti-IFX was more common in both reactive and nonresponder patients than in tolerant/responder patients. Patients who had experienced IgE-mediated reactions displayed significantly higher IgG4 anti-IFX than IgE-negative reactive patients. The majority of patients tested positive for IgG4 anti-IFX after the first seven infusions.

Conclusions: IgG4 anti-IFX is common in treated patients and a large part of ADA producing patients produce IgG4 antibodies. The IgG4 anti-IFX response does not prevent hypersensitivity reactions to IFX and correlates with the IgE anti-IFX response.

Place, publisher, year, edition, pages
2018. Vol. 73, no 11, p. 2172-2181
Keywords [en]
anti-drug antibodies, hypersensitivity reactions, IgG4, infliximab
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:uu:diva-371402DOI: 10.1111/all.13471ISI: 000450344300007PubMedID: 29719053OAI: oai:DiVA.org:uu-371402DiVA, id: diva2:1273121
Available from: 2018-12-20 Created: 2018-12-20 Last updated: 2019-01-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Movérare, Robert

Search in DiVA

By author/editor
Movérare, Robert
By organisation
Lung- allergy- and sleep research
In the same journal
Allergy. European Journal of Allergy and Clinical Immunology
Rheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 22 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf